anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel biaromatic compounds bound by propinylene bond of the general formula (I)   where Ar means radical of the formula (a)   or (b)  ; R 1  means -OR 6  or -COR 7 ; R 2  means polyester radical including 1-6 carbon atoms and 1-3 oxygen or sulfur atoms and if in the latter case R 4  means linear or branched C 1 -C 20 -alkyl then it is located at ortho- or meta-position relative to the bond Ar-X; R 3  means a lower alkyl or R 2  and R 3  taken in common form 6-membered optionally substituted ring with at least one methyl and/or optionally disjointed by oxygen or sulfur atom; R 4  means H, linear or branched C 1 -C 20 -alkyl or aryl; R 5  means H or -OR 8 ; R 6  means H; R 7  means H, -OR 10  or -N(r)r where rr are H, lower alkyl or taken in common with nitrogen atom they form morpholine ring; R 8  means H or lower alkyl; R 10  means H, linear or branched C 1 -C 20 -alkyl; X means bivalent radical which has formula (d)   from the right to the left or vice versa; R 11  means H or -OR 8 ; R 12/   means H, and salts of compound of the formula (I) when R 1  means carboxylic acid and optical and geometric isomers of indicated compounds of the formula (I). Invention relates to also a pharmaceutical composition eliciting antagonistic activity with respect to retinoic acid receptors and containing compound of the formula (I) and pharmaceutically acceptable carrier. Invention relates to also a cosmetic composition eliciting antagonistic activity with respect to retinoic acid receptors and containing compound of the formula (I) and cosmetically acceptable carrier. EFFECT: new compounds indicated above, valuable pharmacological properties. 13 cl, 1 tbl, 31 ex
BACKGROUND AND AIMS: Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy and defibrillator (CRT-D) hospitalized with BSI were investigated.
METHODS: This is a single-centre, retrospective, cohort analysis including consecutive ICD/CRT-D patients implanted between 2012 and 2021. These patients were screened against a list of all hospitalized patients having positive blood cultures consistent with diagnosed infection in any department of a local public hospital.
RESULTS: The total cohort consisted of 515 patients. Over a median follow-up of 59 months (interquartile range 31-87 months), there were 47 BSI episodes in 36 patients. The majority of patients with BSI (92%) was admitted to non-cardiology units, and in 25 episodes (53%), no cardiac imaging was performed. Nearly all patients (85%) were treated with short-term antibiotics, whereas chronic antibiotic suppression therapy (n = 4) and system extraction (n = 3) were less frequent. Patients with BSI had a nearly seven-fold higher rate (hazard ratio 6.7, 95% confidence interval 3.9-11.2; P < .001) of all-cause mortality.
CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.
Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY - Susceptibility Test Methods).

Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to a methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
BACKGROUND: Lysine demethylase 5C (KDM5C) has been implicated in the development of several human cancers. This study aims to investigate the role of KDM5C in the progression of colorectal cancer (CRC) and explore the associated molecular mechanism.
METHODS: Bioinformatics tools were employed to predict the target genes of KDM5C in CRC. The expression levels of KDM5C and prefoldin subunit 5 (PFDN5) in CRC cells were determined by RT-qPCR and western blot assays. The interaction between KDM5C, H3K4me3, and PFDN5 was validated by chromatin immunoprecipitation. Expression and prognostic values of KDM5C and PFDN5 in CRC were analyzed in a cohort of 72 patients. The function of KDM5C/PFDN5 in c-Myc signal transduction was analyzed by luciferase assay. Silencing of KDM5C and PFDN5 was induced in CRC cell lines to analyze the cell malignant phenotype in vitro and tumorigenic activity in nude mice.
RESULTS: KDM5C exhibited high expression, while PFDN5 displayed low expression in CRC cells and clinical CRC samples. High KDM5C levels correlated with poor survival and unfavorable clinical presentation, whereas elevated PFDN5 correlated with improved patient outcomes. KDM5C mediated demethylation of H3K4me3 on the PFDN5 promoter, suppressing its transcription and thereby enhancing the transcriptional activity of c-Myc. KDM5C knockdown in CRC cells suppressed cell proliferation, migration and invasion, epithelial-mesenchymal transition, and tumorigenic activity while increasing autophagy and apoptosis rates. However, the malignant behavior of cells was restored by the further silencing of PFDN5.
CONCLUSION: This study demonstrates that KDM5C inhibits PFDN5 transcription, thereby activating c-Myc signal transduction and promoting CRC progression.
1320626 Radioactive diagnostic preparations PHILIPS GLOEILAMPENFABRIEKEN N.V. 19 May 1971 [22 May 1970] 15771/  71 Heading A5B [Also in Division G6] A radioactive diagnostic preparation is formed by adding a solution containing technetium-99m to powdered ferrous ascorbate, adjusting the pH to between 7 and 8, and agitating the mixture. The ferrous ascorbate is preferably prepared by freeze drying, and the technetium solution may be obtained by elution of a radioactive technetium generator. The pH may be adjusted by adding a solution of trihydroxymethylaminomethane. The invention also includes a powdered mixture of ferrous ascorbate and an alkaline substance and a kit comprising sterilised powdered ferrous ascorbate in a container and an alkaline substance in a container, for use in the preparation of the radioactive solution. The solution may be used in the scintigraphic examination of the brain and kidneys. Prior art processes referred to comprise adding a technetium solution to a solution of ascorbic acid and ferric chloride or ferrous sulphate.
Invasive micropapillary carcinoma (IMPC) of the breast represents a rare subtype of breast cancer, accounting for 1% to 2% of all breast cancers worldwide. Although clinically asymptomatic, they are usually detected during routine breast screenings. The common symptoms include breast lumps, skin or nipple changes, and nipple discharge. Histopathologically, IMPCs are characterized by tumor cells forming small papillary-like structures inside the glandular spaces, and arranged in an inverted pattern, with their apex pointing toward the center of the gland. This unique morphological feature is critical for diagnosing these cases. Another notable characteristic is its high propensity for lymph node metastasis (LNM). While the precise mechanism of metastasis is not clear, unique cellular arrangement and cellular interactions with the surrounding environment might promote tumorigenesis and higher node positivity. Hence, proper lymph node dissection and assessment are particularly crucial for this type of breast cancer. This review aims to discuss the recent progress in managing IMPC cases.
Adult inpatients and outpatients with a diagnosis of community-acquired bacterial pneumonia were evaluated in 2 pivotal clinical studies. In the first study, 590 patients were enrolled in a prospective, multi-center, unblinded randomized trial comparing levofloxacin 500 mg once daily orally or intravenously for 7 to 14 days to ceftriaxone 1 to 2 grams intravenously once or in equally divided doses twice daily followed by cefuroxime axetil 500 mg orally twice daily for a total of 7 to 14 days. Patients assigned to treatment with the control regimen were allowed to receive erythromycin (or doxycycline if intolerant of erythromycin) if an infection due to atypical pathogens was suspected or proven. Clinical and microbiologic evaluations were performed during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Clinical success (cure plus improvement) with levofloxacin at 5 to 7 days posttherapy, the primary efficacy variable in this study, was superior (95%) to the control group (83%). The 95% CI for the difference of response rates (levofloxacin  minus comparator) was [-6, 19]. In the second study, 264 patients were enrolled in a prospective, multi-center, non-comparative trial of 500 mg levofloxacin administered orally or intravenously once daily for 7 to 14 days. Clinical success for clinically evaluable patients was 93%. For both studies, the clinical success rate in patients with atypical pneumonia due to Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila were 96%, 96%, and 70%, respectively. Microbiologic eradication rates across both studies are presented in Table 10.

Community-Acquired Pneumonia Due to Multi-Drug Resistant Streptococcus pneumoniae  
  
Levofloxacin was effective for the treatment of community-acquired pneumonia caused by multi-drug resistant Streptococcus pneumoniae (MDRSP). MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins (e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole). Of 40 microbiologically evaluable patients with MDRSP isolates, 38 patients (95.0%) achieved clinical and bacteriologic success at post-therapy. The clinical and bacterial success rates are shown in Table 11.

Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in Table 12.
Interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks.
The invention relates to a novel use of a YT cell line that is suitable for treating malignant diseases, in particular multiple myeloma and malignant lymphoma as well as viral infections, including hepatitis, in particular hepatitis C, and for producing interferon gamma. The cell line can be used in medical science and the pharmaceutical industry. The aim of the invention is to allow a novel therapy of malignant tumors and viral infections. The invention is implemented according to the patent claims. The central point of the invention is a natural NK cell line YT. Surprisingly, said cell line has been found to be capable of treating a series of diseases.
On Pancreatic Clamp Visit 1 (MH Protocol), the insulin infusion rate (IIR) will be set to approximately replicate participants' endogenous fasting serum insulin levels based on screening visit data for the duration of the pancreatic clamp. On Pancreatic Clamp Visit 2 (RE Protocol), the IIR will be set to reduce serum insulin levels to roughly 50% of the screening fasting serum insulin for the duration of the pancreatic clamp. In both cases, plasma glucose will be clamped to approximately 140 mg/dL +/- 10%.
Intestinal metaplasia (IM) is a premalignant condition that increases the risk for subsequent gastric cancer (GC). Traditional Chinese medicine generally plays a role in the treatment of IM, and the phytochemical naringenin used in Chinese herbal medicine has shown therapeutic potential for the treatment of gastric diseases. However, naringenin's specific effect on IM is not yet clearly understood. Therefore, this study identified potential gene targets for the treatment of IM through bioinformatics analysis and experiment validation. Two genes (MTTP and APOB) were selected as potential targets after a comparison of RNA-seq results of clinical samples, the GEO dataset (GSE78523), and naringenin-related genes from the GeneCards database. The results of both cell and animal experiments suggested that naringenin can improve the changes in the intestinal epithelial metaplasia model via MTTP/APOB expression. In summary, naringenin likely inhibits the MTTP/APOB axis and therefore inhibits IM progression. These results support the development of naringenin as an anti-IM agent and may contribute to the discovery of novel IM therapeutic targets.
Sirolimus: Concomitant administration of Noxafil with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity. Therefore, posaconazole is contraindicated with sirolimus [see Contraindications (4.2) and Clinical Pharmacology (12.3)].

Tacrolimus: Noxafil has been shown to significantly increase the Cmax and AUC of tacrolimus. At initiation of posaconazole treatment, reduce the tacrolimus dose to approximately one-third of the original dose. Frequent monitoring of tacrolimus whole blood trough concentrations should be performed during and at discontinuation of Noxafil treatment and the tacrolimus dose adjusted accordingly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Cyclosporine: Noxafil has been shown to increase cyclosporine whole blood concentrations in heart transplant patients upon initiation of Noxafil treatment. It is recommended to reduce cyclosporine dose to approximately three-fourths of the original dose upon initiation of Noxafil treatment. Frequent monitoring of cyclosporine whole blood trough concentrations should be performed during and at discontinuation of Noxafil treatment and the cyclosporine dose adjusted accordingly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
* Thrombosis may occur with immune globulin (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors (see Warnings and Precautions [5.2], Patient Counseling Information [17]).
  * Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients.
  * Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose.
  * For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity ( see Dosage and Administration [2.1, 2.3], Warnings and Precautions [5.3]).
PURPOSE:To obtain the subject crystals, remarkably improved in purity and stability and useful as a remedy for wounds, etc., by dissolving a basic fibroblastic growth factor (bFGF) protein in a solvent consisting essentially of water in a high concentration, adding a water-soluble substance thereto and depositing the crystals. CONSTITUTION:An expression vector containing a DNA capable of coding a bFGF protein is introduced into Escherichia coli, etc., which is then transformed. The resultant transformant is cultured to prepare a bFGF protein, which is subsequently dissolved in a solvent consisting essentially of water in a high concentration. A water-soluble substance (e.g. polyethylene glycol) is then added to the obtained solution and regulated to pH6.0 with an aqueous solution of sodium citrate, etc. The regulated solution is subsequently allowed to stand for 4 days to deposit crystals. Thereby, the objective crystals of the bFGF protein are obtained.
This study tests the efficacy of embedding educational information (i.e., pediatric anticipatory guidance) into baby books that first-time mothers read to their infants. This 3-group longitudinal study recruited first-time mothers in their third trimester of pregnancy, randomly assigned them to conditions, and followed them until the child was 18 months of age. One group received educational baby books, another group was given the same illustrated books with non-educational text, and the third group was not given any books. Thus, the effects of educational reading could be parsed from the effects of reading alone. The study aimed to test whether embedding pediatric anticipatory guidance in picture books is an effective method for increasing maternal knowledge of child development, parenting strategies, and safety practices, improving parenting beliefs and attitudes (e.g., parenting efficacy, importance of reading, use of corporal punishment), supporting optimal parenting practices (e.g., breastfeeding and nutrition, responsiveness, safety practices), improving maternal health (stress, depression), and supporting children's healthier development (injuries, illness, immunizations, and linguistic, social, and cognitive development).

Survey and observational data collection occurred in participants' homes during their third trimester of pregnancy and when their child was 2, 4, 6, 9, 12, and 18 months of age. Twelve phone call interviews were conducted between these home visits. When children were 18 months, a retrospective medical chart audit was conducted.
PURPOSE:To provide an antiasthmatic agent contaning dibenz[b,e]oxepin derivatives, some of which are novel, as active component. CONSTITUTION:The objective agent contains the dibenz[b,e]oxepin derivative of formulaI(R1 is 1-5C alkyl or halogen; R2 and R3 are 1-5C alkyl) (the compound of formulaIwherein R2 and R3 are methyl, and R1 is other than methyl, F, Cl and Br is novel compound) or its acid addition salt. The compound of formulaIcan be prepared by reacting the compound of formula II with equimolar amount of the compound of formula III in an inert solvent (e.g. CH2Cl2) at a temperature between room temperature and the boiling point of the solvent for 0.5-2hr under stirring. The compound of formulaIexhibits remarkable antiasthmatic activity by PCA reaction, and is administrable orally or parenterally as an antiasthmatic agent. Effective dose: 1-20mg/kg/day, preferably in 3-4 doses daily.
The invention relates to the field of cryptography protocols and network security, provides a cloud-assisted medical data secure sharing method based on a blockchain, and aims to solve the problems that medical data are easy to tamper, patient data control rights are lost and a cloud server stores a large amount of repeated data. The method comprises four steps of system initialization, EMR data generation, data encryption uploading and data sharing. The system initialization realizes safe and reliable network construction and entity registration through a block chain technology. EMR data is generated and encrypted by the doctor and uploaded to the cloud server, wherein a ciphertext-based deduplication technique is employed. In the data sharing stage, the data user initiates an access request to the patient through the blockchain account, and after the patient is authorized, the user can download the decrypted EMR data. The invention guarantees the privacy, the integrity and the auditability of medical data through the encryption technology and the tamper-proof characteristic of the blockchain, and improves the storage efficiency.
An antimicrobial agent includes a metal ion in a hydrophilic polymer binder or carrier. The metal ion is preferably a silver ion and the hydrophilic polymer preferably comprises a sulfonated polyurethane or sulfonated polystyrene. According to a method of the invention, the antimicrobial agent is dissolved in dimethyl acetamide DMA, applied to paper by spraying, squeegee or the like and dried in an oven to flash off the solvent. The antimicrobial agent can be applied to other products by spraying and/or dipping and then drying to flash off solvent. According to another embodiment of the invention, the antimicrobial agent includes a water soluble polymer, at least one organic acid (e.g., one or more carboxylic acids such as acetic acid, formic acid, citric acid, malefic acid, ascorbic acid, salicyclic acid), and oligodynamic metal ions which react with counter-ions of the polymer such that the metal ions are bound to corresponding counter-ions, and the polymer controls a sustained release of said metal ion. The agent may also include a non-organic acid. (preferably boric acid and/or dictylborate). The water soluble polymer is preferably a sulfonated polymer (e.g., a sulfonated polyurethane, a sulfonated polystyrene, or a mixture thereof).
PURPOSE:To provide a hydrophilic tacky adhesive compsn. which has an excellent balance of adhesiveness and cohesive strength and which comprises a particular polymaltotriose, a particular acrylic polymer, and a water retentive softener. CONSTITUTION:A tacky adhesive compsn. comprising a polymaltotriose having a chemical structure in which maltotriose units are combined through alpha-1,6 bonds; at least one acrylic polymer selected from among a homopolymer of acrylic acid, a salt of the homopolymer, a copolymer comprising acrylic acid units as major structural units, and a slat of this copolymer; and a water- retentive softener. In preparing the aforesaid tacky adhesive compsn., a crosslinking agent for an acrylic polymer, such as a polyvalent metal, may be added. Such an acrylic polymer improves the water retentivity of the final tacky compsn. Examples of the softener include glycerin, diglycerin, triglycerin, sorbitol, and reduced maltose.
A randomized controlled pilot study will be conducted. Forty patients with severe UL paresis will be included. Patients with severe hemiparesis after stroke will be allocated to one of two treatment groups by a computerized randomization program. Patients in the intervention group will receive training with a BCI system paired with functional electrical stimulation and visual feedback (RecoveriX, gtec, Austria) as part of their rehabilitation. The targeted number of training sessions in the intervention group is 12. Patients in the control group will receive conventional upper limb training. All patients will receive other rehabilitation according to their needs.

Patients will be assessed by blinded raters before and after the intervention and 3 months post stroke. Main endpoint will be UL motor function assessed by Action Research Arm Test (ARAT) at 3 months post stroke. Other outcome measures comprise Fugl Meyer Motor Assessment and Functional Independence Measure. The patients and therapists' experience with this type of training will be evaluated with questionnaires and interviews.